Systematic Review of Studies Investigating Hospital Readmissions in Pediatric Oncology.

IF 2.4 3区 医学 Q2 HEMATOLOGY Pediatric Blood & Cancer Pub Date : 2024-11-25 DOI:10.1002/pbc.31459
Hadeel Hassan, Yujie Chen, Amy Duoli Lu, Santiago Eduardo Arciniegas, Adam Paul Yan, Lin Lawrence Guo, Lillian Sung
{"title":"Systematic Review of Studies Investigating Hospital Readmissions in Pediatric Oncology.","authors":"Hadeel Hassan, Yujie Chen, Amy Duoli Lu, Santiago Eduardo Arciniegas, Adam Paul Yan, Lin Lawrence Guo, Lillian Sung","doi":"10.1002/pbc.31459","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This systematic review aimed to identify and synthesize evidence on hospital readmissions among pediatric oncology patients, focusing on the indications, risk factors, and proposed strategies to prevent readmissions.</p><p><strong>Method: </strong>The review followed PRISMA 2020 guidelines. Databases including Embase, Medline, Scopus, Mendeley, and Google Scholar were searched. Studies examining hospital readmission as a main outcome in pediatric cancer patients, including those undergoing surgical oncology procedures or receiving hematopoietic cell transplantation, were included. Quality assessment was undertaken using the Newcastle-Ottawa Scale and PROBAST tool.</p><p><strong>Results: </strong>A total of 18 studies met the inclusion criteria. The studies spanned from 2008 to 2023, with an increase in publications from 2020 onward (61%). Fever and infection were the most common readmission indications. Statistically significant risk factors reported included younger age, specific cancer types (e.g., acute lymphoblastic leukemia), and socioeconomic factors. Prevention strategies proposed included early follow-up, tailored anticipatory guidance, discharge education, and specialized care at pediatric oncology centers.</p><p><strong>Conclusions: </strong>This systematic review highlights the multifaceted nature of hospital readmissions in pediatric oncology patients and the need for standardized definitions, additional studies, and comprehensive interventions. Future research should focus on high-quality prospective studies, integration of predictive analytics, and addressing socioeconomic disparities to improve patient outcomes.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":" ","pages":"e31459"},"PeriodicalIF":2.4000,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Blood & Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pbc.31459","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: This systematic review aimed to identify and synthesize evidence on hospital readmissions among pediatric oncology patients, focusing on the indications, risk factors, and proposed strategies to prevent readmissions.

Method: The review followed PRISMA 2020 guidelines. Databases including Embase, Medline, Scopus, Mendeley, and Google Scholar were searched. Studies examining hospital readmission as a main outcome in pediatric cancer patients, including those undergoing surgical oncology procedures or receiving hematopoietic cell transplantation, were included. Quality assessment was undertaken using the Newcastle-Ottawa Scale and PROBAST tool.

Results: A total of 18 studies met the inclusion criteria. The studies spanned from 2008 to 2023, with an increase in publications from 2020 onward (61%). Fever and infection were the most common readmission indications. Statistically significant risk factors reported included younger age, specific cancer types (e.g., acute lymphoblastic leukemia), and socioeconomic factors. Prevention strategies proposed included early follow-up, tailored anticipatory guidance, discharge education, and specialized care at pediatric oncology centers.

Conclusions: This systematic review highlights the multifaceted nature of hospital readmissions in pediatric oncology patients and the need for standardized definitions, additional studies, and comprehensive interventions. Future research should focus on high-quality prospective studies, integration of predictive analytics, and addressing socioeconomic disparities to improve patient outcomes.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
儿科肿瘤再住院调查研究的系统性回顾。
目的:本系统性综述旨在识别和综合有关儿科肿瘤患者再入院的证据,重点关注适应症、风险因素以及预防再入院的建议策略:综述遵循 PRISMA 2020 指南。检索的数据库包括 Embase、Medline、Scopus、Mendeley 和 Google Scholar。包括接受肿瘤外科手术或造血细胞移植的儿科癌症患者在内的儿科癌症患者再入院作为主要结果的研究均被纳入其中。采用纽卡斯尔-渥太华量表和PROBAST工具进行质量评估:共有 18 项研究符合纳入标准。这些研究的时间跨度为 2008 年至 2023 年,其中 2020 年以后发表的研究有所增加(61%)。发热和感染是最常见的再入院指征。据报道,具有统计学意义的风险因素包括年龄较小、特定癌症类型(如急性淋巴细胞白血病)和社会经济因素。提出的预防策略包括早期随访、有针对性的预期指导、出院教育以及儿科肿瘤中心的专业护理:本系统综述强调了儿科肿瘤患者再入院的多面性,以及标准化定义、额外研究和综合干预的必要性。未来的研究应侧重于高质量的前瞻性研究、预测分析的整合以及解决社会经济差异问题,以改善患者的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pediatric Blood & Cancer
Pediatric Blood & Cancer 医学-小儿科
CiteScore
4.90
自引率
9.40%
发文量
546
审稿时长
1.5 months
期刊介绍: Pediatric Blood & Cancer publishes the highest quality manuscripts describing basic and clinical investigations of blood disorders and malignant diseases of childhood including diagnosis, treatment, epidemiology, etiology, biology, and molecular and clinical genetics of these diseases as they affect children, adolescents, and young adults. Pediatric Blood & Cancer will also include studies on such treatment options as hematopoietic stem cell transplantation, immunology, and gene therapy.
期刊最新文献
X-Linked Lymphoproliferative Disease Associated Hemophagocytic Lymphohistiocytosis Diagnosed Expeditiously With Ultra-Rapid Whole-Genome Sequencing. Systematic Review of Studies Investigating Hospital Readmissions in Pediatric Oncology. Clinical Utility of a Novel Triplex Digital PCR Assay for Clone Monitoring in Sequential and Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia Patients. Concurrent Unilateral Retinoblastoma and Giant Suprasellar Pilomyxoid Astrocytoma. Management of Ganglioneuroma and Ganglioneuroblastoma Intermixed: A United Kingdom Children's Cancer and Leukaemia Group (UK CCLG) Nationwide Study Report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1